Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1809 results
December 2020
-
Media Release
Novartis announces positive FDA Advisory Committee recommendation for use of Entresto® to treat patients with HFpEF
The Committee voted 12 to 1 that the data presented support the use of Entresto in treatment of patients with heart failure with preserved ejection fraction (HFpEF)Potential Q1 2021 sNDA approval… -
Media Release
Novartis reports positive topline results from second Phase III trial of Beovu® in patients with diabetic macular edema
In Phase III KESTREL study, Beovu (brolucizumab 6 mg) achieved its primary endpoint of non-inferiority to aflibercept 2 mg in change in best-corrected visual acuity (BCVA) at year one (week 52)1In a… -
Featured News
The RUXCOVID clinical trial
The RUXCOVID clinical trial highlights the Novartis commitment to leverage our expertise and resources to support the global response to the COVID-19 pandemic.
-
Media Release
Novartis provides update on RUXCOVID study of ruxolitinib for hospitalized patients with COVID-19
Phase III study did not meet its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications (death, mechanical ventilation or ICU care)1 Detailed… -
Media Release
Novartis receives EU approval for Leqvio®* (inclisiran), a first-in-class siRNA to lower cholesterol with two doses a year**
Leqvio® (inclisiran) is the first and only approved small-interfering RNA (siRNA) low-density lipoprotein cholesterol (LDL-C) lowering treatment in Europe1-3 Cardiovascular disease causes 3.9… -
Media Release
Novartis Kisqali® data demonstrate superior benefit across main intrinsic subtypes in metastatic breast cancer
Findings presented at SABCS from largest intrinsic subtype analysis show Kisqali is unique among CDK4/6 inhibitors, delivers consistent efficacy across main HR+/HER2- intrinsic subtypes1Benefit seen… -
Media Release
Novartis Kisqali® demonstrates nearly five years median overall survival in metastatic breast cancer
MONALEESA-7 median overall survival (OS) results reinforce Kisqali as the CDK4/6 inhibitor with unrivaled OS evidence1Kisqali plus endocrine therapy had a median OS of nearly five years (58.7… -
Media Release
Novartis investigational STAMP inhibitor asciminib (ABL001) shows superior MMR rate to Bosulif®* in chronic myeloid leukemia trial
At 24 weeks, asciminib nearly doubled the major molecular response (MMR) rate compared to Bosulif® (bosutinib)*, in patients resistant to, or intolerant of, at least two prior tyrosine kinase… -
Media Release
Novartis analyses confirm benefit of Kymriah® with clinically meaningful rates of complete response seen in patients with certain advanced lymphomas
Interim analysis from the investigational ELARA study shows, 65% of patients with r/r follicular lymphoma evaluated for efficacy achieved a complete response and the overall response rate was 83%1… -
Media Release
Novartis announces first data from REACH3 trial showing Jakavi® (ruxolitinib) significantly improved outcomes in patients with steroid-resistant/dependent chronic GvHD
Results of REACH3 trial also demonstrate significant improvements in failure-free survival (FFS) and patient-reported symptoms1Chronic graft-versus-host disease (GvHD) is a life-threatening… -
Featured News
The Co-Creating Impact Summit for the society and the planet
The Co-Creating Impact Summit happening on December 9th, 2020, will gather experts inside and outside of Novartis to continue our work of improving our impact on the society and the planet.
-
Featured News
Why healthcare’s digital moment is now
Novartis Chief Digital Officer, Bertrand Bodson, and Microsoft Corporate Vice President Research & Incubation, Peter Lee, discussed why healthcare’s digital moment is now.